Korea-based company Samsung has announced its plans to bring irregular heart rhythm notifications (IRHN) to 13 different markets around the world.

Samsung devices have been trailing Apple, which released IHRN on its wearable devices back in 2018.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The IHRN feature will now give Samsung users the ability to monitor arrhythmia with notifications and allow them to detect atrial fibrillation (AFib), a condition that affects 2% of the world’s population.

The planned rollout of this feature comes after it received approval from the Korean Ministry of Food and Drug Safety (MFDS). In May 2023, the IHRN feature was also approved by the US Food and Drug Administration (FDA).

The IHRN feature will be introduced to 13 markets, which include Argentina, Azerbaijan, Korea and the US.

The feature will join existing Samsung Health Monitor app functions such as observation of blood pressure and electrocardiogram (ECG).

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

It will initially be introduced on the One UI 5 Watch software update and will be later available in previous editions.

Expressing his excitement for innovation of the Galaxy Watch, Samsung Electronics vice-president and digital health team head Hon Pak said: “Cardiovascular disease remains one of the main causes of death around the world, and we’re committed to empowering our users to stay informed about their heart health by providing monitoring tools, including blood pressure measurement and irregular heart rhythm notification.”

Since its inception in 2020, the Samsung Health Monitor app is now available in 74 international markets and has supported its 150 million Galaxy Watch users to track their heart health.

Medical Device Network Excellence Awards - Nominations Closed

Nominations are now closed for the Medical Device Network Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
SC MEDICA’s minimally invasive, radiation free spinal facet fixation system, FFX® is transforming spinal pain management and improving outcomes for surgeons and patients alike. Learn how SC MEDICA’s award-winning technology is redefining standards in facet joint pain treatment.

Discover the Impact